Last reviewed · How we verify
Urinary FSH
Urinary FSH is a purified preparation of follicle-stimulating hormone extracted from human urine that stimulates follicle development and estrogen production in women undergoing fertility treatment.
Urinary FSH is a purified preparation of follicle-stimulating hormone extracted from human urine that stimulates follicle development and estrogen production in women undergoing fertility treatment. Used for Ovarian stimulation in assisted reproductive technology (ART) cycles, Anovulation and infertility in women.
At a glance
| Generic name | Urinary FSH |
|---|---|
| Also known as | Fostipur, Bravelle |
| Sponsor | IVI Madrid |
| Drug class | Gonadotropin |
| Target | FSH receptor (FSHR) |
| Modality | Small molecule |
| Therapeutic area | Reproductive Medicine / Fertility |
| Phase | FDA-approved |
Mechanism of action
FSH (follicle-stimulating hormone) is a gonadotropin that binds to FSH receptors on ovarian granulosa cells, promoting follicular growth and maturation. The urinary-derived formulation provides bioactive FSH for controlled ovarian stimulation in assisted reproductive technology cycles. This leads to development of multiple ovarian follicles and increased estrogen levels necessary for egg retrieval.
Approved indications
- Ovarian stimulation in assisted reproductive technology (ART) cycles
- Anovulation and infertility in women
Common side effects
- Ovarian hyperstimulation syndrome (OHSS)
- Headache
- Injection site reactions
- Abdominal pain/bloating
- Nausea
Key clinical trials
- 150 IU vs. 225 IU FSH in Normal Responders: The OPTIMAL-DOSE Trial (PHASE3)
- Ovarian Hyperstimulation and Fibrin Clot Properties. (NA)
- Comparing IVF/ICSI Cycle Outcomes of Post Ovulation Ovarian Stimulation Protocol With Elonva Without GnRH Antagonist to Follicular Phase Day 2 Stimulation Fixed Day 5 Antagonist Protocol
- Does Recombinant FSH (rFSH, i.g. Gonal F®) as Compared to Human Menopausal Gonadotrophin (hMG) Affect Telomere Length of Cumulus Cells During Antral Follicle Growth and Impact Blastocyst Status?
- Continuous Double Ovarian Stimulation. (PHASE4)
- Brain Irradiation for Childhood Cancer - Endocrine Monitoring During the First Years (NA)
- Polycystic Ovary Syndrome and Urinary Tract Stones: a BMI-Adjusted Analysis in Iraqi Women
- Quantum Menstrual Health Monitoring Study
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Urinary FSH CI brief — competitive landscape report
- Urinary FSH updates RSS · CI watch RSS
- IVI Madrid portfolio CI